These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

361 related articles for article (PubMed ID: 26801070)

  • 1. Clinical Validation and Implementation of a Targeted Next-Generation Sequencing Assay to Detect Somatic Variants in Non-Small Cell Lung, Melanoma, and Gastrointestinal Malignancies.
    Fisher KE; Zhang L; Wang J; Smith GH; Newman S; Schneider TM; Pillai RN; Kudchadkar RR; Owonikoko TK; Ramalingam SS; Lawson DH; Delman KA; El-Rayes BF; Wilson MM; Sullivan HC; Morrison AS; Balci S; Adsay NV; Gal AA; Sica GL; Saxe DF; Mann KP; Hill CE; Khuri FR; Rossi MR
    J Mol Diagn; 2016 Mar; 18(2):299-315. PubMed ID: 26801070
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Implementation of next generation sequencing technology for somatic mutation detection in routine laboratory practice.
    Giardina T; Robinson C; Grieu-Iacopetta F; Millward M; Iacopetta B; Spagnolo D; Amanuel B
    Pathology; 2018 Jun; 50(4):389-401. PubMed ID: 29752127
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Comparison of different massive parallel sequencing platforms for mutation profiling in formalin-fixed and paraffin-embedded samples].
    Jiang RR; Wang YJ; Teng XD; Xiao L; Bu H; Ye F
    Zhonghua Bing Li Xue Za Zhi; 2018 Aug; 47(8):591-596. PubMed ID: 30107663
    [No Abstract]   [Full Text] [Related]  

  • 4. Performance validation of an amplicon-based targeted next-generation sequencing assay and mutation profiling of 648 Chinese colorectal cancer patients.
    Wang Y; Liu H; Hou Y; Zhou X; Liang L; Zhang Z; Shi H; Xu S; Hu P; Zheng Z; Liu R; Tang T; Ye F; Liang Z; Bu H
    Virchows Arch; 2018 Jun; 472(6):959-968. PubMed ID: 29705968
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of OncoPanel: A Targeted Next-Generation Sequencing Assay for the Detection of Somatic Variants in Cancer.
    Garcia EP; Minkovsky A; Jia Y; Ducar MD; Shivdasani P; Gong X; Ligon AH; Sholl LM; Kuo FC; MacConaill LE; Lindeman NI; Dong F
    Arch Pathol Lab Med; 2017 Jun; 141(6):751-758. PubMed ID: 28557599
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Development of a gene panel for next-generation sequencing of clinically relevant mutations in cell-free DNA from cancer patients.
    Malapelle U; Mayo de-Las-Casas C; Rocco D; Garzon M; Pisapia P; Jordana-Ariza N; Russo M; Sgariglia R; De Luca C; Pepe F; Martinez-Bueno A; Morales-Espinosa D; González-Cao M; Karachaliou N; Viteri Ramirez S; Bellevicine C; Molina-Vila MA; Rosell R; Troncone G
    Br J Cancer; 2017 Mar; 116(6):802-810. PubMed ID: 28170370
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Development and validation of an ultra-high sensitive next-generation sequencing assay for molecular diagnosis of clinical oncology.
    Liang J; She Y; Zhu J; Wei L; Zhang L; Gao L; Wang Y; Xing J; Guo Y; Meng X; Li P
    Int J Oncol; 2016 Nov; 49(5):2088-2104. PubMed ID: 27826616
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Assessing the Diagnostic Yield of Targeted Next-Generation Sequencing for Melanoma and Gastrointestinal Tumors.
    Garg S; Grenier S; Misyura M; Sukhai MA; Thomas M; Kamel-Reid S; Stockley T
    J Mol Diagn; 2020 Apr; 22(4):467-475. PubMed ID: 32036084
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Validating a targeted next-generation sequencing assay and profiling somatic variants in Chinese non-small cell lung cancer patients.
    Jiang R; Zhang B; Teng X; Hu P; Xu S; Zheng Z; Liu R; Tang T; Ye F
    Sci Rep; 2020 Feb; 10(1):2070. PubMed ID: 32034196
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Clinical applicability and cost of a 46-gene panel for genomic analysis of solid tumours: Retrospective validation and prospective audit in the UK National Health Service.
    Hamblin A; Wordsworth S; Fermont JM; Page S; Kaur K; Camps C; Kaisaki P; Gupta A; Talbot D; Middleton M; Henderson S; Cutts A; Vavoulis DV; Housby N; Tomlinson I; Taylor JC; Schuh A
    PLoS Med; 2017 Feb; 14(2):e1002230. PubMed ID: 28196074
    [TBL] [Abstract][Full Text] [Related]  

  • 11. High-throughput detection of clinically targetable alterations using next-generation sequencing.
    Vendrell JA; Grand D; Rouquette I; Costes V; Icher S; Selves J; Larrieux M; Barbe A; Brousset P; Solassol J
    Oncotarget; 2017 Jun; 8(25):40345-40358. PubMed ID: 28404952
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integration of Technical, Bioinformatic, and Variant Assessment Approaches in the Validation of a Targeted Next-Generation Sequencing Panel for Myeloid Malignancies.
    Thomas M; Sukhai MA; Zhang T; Dolatshahi R; Harbi D; Garg S; Misyura M; Pugh T; Stockley TL; Kamel-Reid S
    Arch Pathol Lab Med; 2017 Jun; 141(6):759-775. PubMed ID: 28557600
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bioinformatics Basics for High-Throughput Hybridization-Based Targeted DNA Sequencing from FFPE-Derived Tumor Specimens: From Reads to Variants.
    Sun S; Murray SS
    Methods Mol Biol; 2019; 1908():37-48. PubMed ID: 30649719
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatic mutation analysis in melanoma using targeted next generation sequencing.
    Miraflor AP; de Abreu FB; Peterson JD; Turner SA; Amos CI; Tsongalis GJ; Yan S
    Exp Mol Pathol; 2017 Oct; 103(2):172-177. PubMed ID: 28822769
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of an NGS mutation detection panel for melanoma.
    Reiman A; Kikuchi H; Scocchia D; Smith P; Tsang YW; Snead D; Cree IA
    BMC Cancer; 2017 Feb; 17(1):150. PubMed ID: 28228113
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Frequency of Somatic TP53 Mutations in Combination with Known Pathogenic Mutations in Colon Adenocarcinoma, Non-Small Cell Lung Carcinoma, and Gliomas as Identified by Next-Generation Sequencing.
    Shajani-Yi Z; de Abreu FB; Peterson JD; Tsongalis GJ
    Neoplasia; 2018 Mar; 20(3):256-262. PubMed ID: 29454261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Microfluidics-based EGFR mutation detection and its implication in the resource-limited clinical setting.
    Joshi P; Gogte P; Pai T; Gurav M; Dhanawade D; Karnik N; Deshpande G; Kaushal R; Shetty O
    Int J Exp Pathol; 2024 Jun; 105(3):90-99. PubMed ID: 38717047
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Towards standardization of next-generation sequencing of FFPE samples for clinical oncology: intrinsic obstacles and possible solutions.
    Ivanov M; Laktionov K; Breder V; Chernenko P; Novikova E; Telysheva E; Musienko S; Baranova A; Mileyko V
    J Transl Med; 2017 Jan; 15(1):22. PubMed ID: 28137276
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High performance of targeted next generation sequencing on variance detection in clinical tumor specimens in comparison with current conventional methods.
    Su D; Zhang D; Chen K; Lu J; Wu J; Cao X; Ying L; Jin Q; Ye Y; Xie Z; Xiong L; Mao W; Li F
    J Exp Clin Cancer Res; 2017 Sep; 36(1):121. PubMed ID: 28882180
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Identification of novel mutations in FFPE lung adenocarcinomas using DEPArray sorting technology and next-generation sequencing.
    Lee JW; Shin JY; Seo JS
    J Appl Genet; 2018 Aug; 59(3):269-277. PubMed ID: 29525983
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.